Ana Clara Mignaqui, Alejandra Ferella, Cintia Sánchez, Matthew Stuible, Romina Scian, Jorge Filippi, Sabrina Beatriz Cardillo, Yves Durocher, Andrés Wigdorovitz
{"title":"口蹄疫疫苗高cho细胞密度瞬时基因表达系统中病毒样颗粒的优化生产","authors":"Ana Clara Mignaqui, Alejandra Ferella, Cintia Sánchez, Matthew Stuible, Romina Scian, Jorge Filippi, Sabrina Beatriz Cardillo, Yves Durocher, Andrés Wigdorovitz","doi":"10.3390/vaccines13060581","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/objectives: </strong>Foot-and-mouth disease virus (FMDV) poses a continuous threat to livestock health and agricultural economies. Current vaccines require high biosafety standards and are costly to produce. While novel vaccine technologies have been explored, most fail to meet industrial scalability, cost-efficiency, or multiserotype flexibility required for effective FMD control. This study aimed to evaluate the feasibility of using a high-cell density transient gene expression (TGE) system in CHO cells for the production of FMDV virus-like particles (VLPs) as a recombinant vaccine platform.</p><p><strong>Methods: </strong>VLP expression was optimized by adjusting cDNA and polyethyleneimine (PEI) concentrations. Expression yields were compared at 24 and 48 h post-transfection to determine optimal harvest timing. We further tested the system's capacity to express different serotypes and chimeric constructs, incorporating VP1 sequences from various FMDV strains. Immunogenicity was evaluated in swine using VLPs from the A2001 Argentina strain as a model.</p><p><strong>Results: </strong>Optimal VLP expression was achieved at 24 h post-transfection. Chimeric constructs incorporating heterologous VP1 regions were successfully expressed. Immunized pigs developed protective antibody titers as measured by a virus neutralization test (VNT, log<sub>10</sub> titer 1.43) and liquid-phase blocking ELISA (LPBE, titer 2.20) at 28 days post-vaccination (dpv). Titers remained above protective thresholds up to 60 dpv with a single dose. A booster at 28 dpv further elevated titers to levels comparable to those induced by the inactivated vaccine.</p><p><strong>Conclusions: </strong>Our results demonstrate the feasibility of using CHO cell-based TGE for producing immunogenic FMDV VLPs. This platform shows promise for scalable, cost-effective, and biosafe development of recombinant FMD vaccines.</p>","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 6","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197728/pdf/","citationCount":"0","resultStr":"{\"title\":\"Optimized Production of Virus-like Particles in a High-CHO-Cell-Density Transient Gene Expression System for Foot-and-Mouth Disease Vaccine Development.\",\"authors\":\"Ana Clara Mignaqui, Alejandra Ferella, Cintia Sánchez, Matthew Stuible, Romina Scian, Jorge Filippi, Sabrina Beatriz Cardillo, Yves Durocher, Andrés Wigdorovitz\",\"doi\":\"10.3390/vaccines13060581\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/objectives: </strong>Foot-and-mouth disease virus (FMDV) poses a continuous threat to livestock health and agricultural economies. Current vaccines require high biosafety standards and are costly to produce. While novel vaccine technologies have been explored, most fail to meet industrial scalability, cost-efficiency, or multiserotype flexibility required for effective FMD control. This study aimed to evaluate the feasibility of using a high-cell density transient gene expression (TGE) system in CHO cells for the production of FMDV virus-like particles (VLPs) as a recombinant vaccine platform.</p><p><strong>Methods: </strong>VLP expression was optimized by adjusting cDNA and polyethyleneimine (PEI) concentrations. Expression yields were compared at 24 and 48 h post-transfection to determine optimal harvest timing. We further tested the system's capacity to express different serotypes and chimeric constructs, incorporating VP1 sequences from various FMDV strains. Immunogenicity was evaluated in swine using VLPs from the A2001 Argentina strain as a model.</p><p><strong>Results: </strong>Optimal VLP expression was achieved at 24 h post-transfection. Chimeric constructs incorporating heterologous VP1 regions were successfully expressed. Immunized pigs developed protective antibody titers as measured by a virus neutralization test (VNT, log<sub>10</sub> titer 1.43) and liquid-phase blocking ELISA (LPBE, titer 2.20) at 28 days post-vaccination (dpv). Titers remained above protective thresholds up to 60 dpv with a single dose. A booster at 28 dpv further elevated titers to levels comparable to those induced by the inactivated vaccine.</p><p><strong>Conclusions: </strong>Our results demonstrate the feasibility of using CHO cell-based TGE for producing immunogenic FMDV VLPs. This platform shows promise for scalable, cost-effective, and biosafe development of recombinant FMD vaccines.</p>\",\"PeriodicalId\":23634,\"journal\":{\"name\":\"Vaccines\",\"volume\":\"13 6\",\"pages\":\"\"},\"PeriodicalIF\":5.2000,\"publicationDate\":\"2025-05-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12197728/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccines\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3390/vaccines13060581\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13060581","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景/目的:口蹄疫病毒(FMDV)对牲畜健康和农业经济构成持续威胁。目前的疫苗需要很高的生物安全标准,而且生产成本很高。虽然已经探索了新的疫苗技术,但大多数疫苗无法满足有效控制口蹄疫所需的工业可扩展性、成本效益或多血清型灵活性。本研究旨在评估在CHO细胞中使用高密度瞬时基因表达(TGE)系统生产FMDV病毒样颗粒(VLPs)作为重组疫苗平台的可行性。方法:通过调节cDNA和聚乙烯亚胺(PEI)浓度来优化VLP的表达。转染后24和48 h比较表达量,以确定最佳收获时间。我们进一步测试了该系统表达不同血清型和嵌合结构的能力,纳入了来自不同FMDV菌株的VP1序列。以A2001阿根廷毒株的VLPs为模型,对猪的免疫原性进行了评价。结果:转染后24 h VLP表达达到最佳。成功表达了包含异源VP1区域的嵌合构建体。接种后28天,通过病毒中和试验(VNT, log10滴度1.43)和液相阻断ELISA (LPBE,滴度2.20)测定免疫猪产生保护性抗体滴度(dpv)。单次注射后滴度仍高于保护阈值,高达60 dpv。28dpv加强剂进一步将滴度提高到与灭活疫苗诱导的水平相当的水平。结论:我们的结果证明了利用CHO细胞为基础的TGE制备免疫原性FMDV VLPs的可行性。该平台显示了可扩展、具有成本效益和生物安全的重组口蹄疫疫苗开发的前景。
Optimized Production of Virus-like Particles in a High-CHO-Cell-Density Transient Gene Expression System for Foot-and-Mouth Disease Vaccine Development.
Background/objectives: Foot-and-mouth disease virus (FMDV) poses a continuous threat to livestock health and agricultural economies. Current vaccines require high biosafety standards and are costly to produce. While novel vaccine technologies have been explored, most fail to meet industrial scalability, cost-efficiency, or multiserotype flexibility required for effective FMD control. This study aimed to evaluate the feasibility of using a high-cell density transient gene expression (TGE) system in CHO cells for the production of FMDV virus-like particles (VLPs) as a recombinant vaccine platform.
Methods: VLP expression was optimized by adjusting cDNA and polyethyleneimine (PEI) concentrations. Expression yields were compared at 24 and 48 h post-transfection to determine optimal harvest timing. We further tested the system's capacity to express different serotypes and chimeric constructs, incorporating VP1 sequences from various FMDV strains. Immunogenicity was evaluated in swine using VLPs from the A2001 Argentina strain as a model.
Results: Optimal VLP expression was achieved at 24 h post-transfection. Chimeric constructs incorporating heterologous VP1 regions were successfully expressed. Immunized pigs developed protective antibody titers as measured by a virus neutralization test (VNT, log10 titer 1.43) and liquid-phase blocking ELISA (LPBE, titer 2.20) at 28 days post-vaccination (dpv). Titers remained above protective thresholds up to 60 dpv with a single dose. A booster at 28 dpv further elevated titers to levels comparable to those induced by the inactivated vaccine.
Conclusions: Our results demonstrate the feasibility of using CHO cell-based TGE for producing immunogenic FMDV VLPs. This platform shows promise for scalable, cost-effective, and biosafe development of recombinant FMD vaccines.
VaccinesPharmacology, Toxicology and Pharmaceutics-Pharmacology
CiteScore
8.90
自引率
16.70%
发文量
1853
审稿时长
18.06 days
期刊介绍:
Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.